PTC THERAPEUTICS INC (PTCT)

US69366J2006 - Common Stock

27.95  +0.88 (+3.25%)

After market: 27.95 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
380.8M
24.04%
538.6M
41.44%
698.8M
29.74%
963.21M
37.84%
EBITDA
YoY % growth
-377.71M
-80.71%
-310.27M
17.85%
-285.16M
8.09%
-131.346M
53.94%
N/AN/AN/AN/AN/A
EBIT
YoY % growth
-421.2M
-74.63%
-374.4M
11.11%
-414M
-10.58%
-364.356M
11.99%
Operating Margin
-110.61%-69.51%-59.24%-37.83%
EPS
YoY % growth
-6.54
-46.31%
-7.43
-13.61%
-7.33
1.35%
-5.98
18.41%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth
0.54
128.65%
Revenue
Q2Q % growth
326.5M
95.04%
EBITDA
Q2Q % growth
100.99M
EBIT
Q2Q % growth
91.097M
154.58%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
-1.76
-15.03%
-1.19-0.57-47.41%
Q2 2023
Q2Q % growth
-2.66
-24.88%
-1.27-1.39-109.52%
Q1 2023
Q2Q % growth
-1.88
-5.62%
-1.32-0.56-41.94%
Q4 2022
Q2Q % growth
-1.89
6.90%
-1.62-0.27-16.38%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
196.6M
-9.44%
214.4M-17.8M-8.30%
Q2 2023
Q2Q % growth
213.8M
29.18%
211.13M2.67M1.26%
Q1 2023
Q2Q % growth
220.4M
48.22%
204.49M15.91M7.78%
Q4 2022
Q2Q % growth
167.4M
1.33%
192.92M-25.52M-13.23%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS5.48% 70.15% 0% -3.42%
Revenue0.48% 4% 0% 0.43%